



NEONATAL

SURFACTANT (Bovine) BERACTANT (Survanta®)




This document should be read in conjunction with this [DISCLAIMER](#)

Restricted: Requires Neonatologist review within 24 hours of initiation

For all indications, Survanta® is the most cost-effective and hence preferred surfactant preparation within the WNHS NICU, except in extremely preterm infants (≤ 25 weeks) where Curosurf is to be used or as per the Neonatal Consultant

Presentation	Vial: 25mg/mL (8mL)
Classification	Pulmonary Surfactant – derived from natural bovine lung extract
Indication	Treatment and Prevention of Respiratory Distress Syndrome
Dose	Intratracheal Administration ONLY 4mL/kg (100mg/kg) per dose Dose may be repeated every 6 hours as required. Maximum of 4 doses in 48 hours of life
Monitoring	Continuous oxygen saturation and cardiorespiratory monitoring Evaluate clinical condition before administration and for 30 minutes after each dose.
Guidelines & Resources	CAHS Surfactant Therapy Guideline
Compatible Fluids	Beractant should not be mixed with any other medications or fluids
Preparation	Allow to stand to room temperature for 20 minutes or warm vial in hands. Do not use artificial warming methods. Do not shake vial.
Administration	Do not shake. For intratracheal administration ONLY. Survanta® should NOT be instilled into a main stem bronchus. Refer to Surfactant Therapy Guideline for administration.

Adverse Reactions	Transient bradycardia, oxygen desaturation, hypotension, endotracheal tube reflux or blockage, pallor, vasoconstriction, hypo/hyper-tension, apnoea, hypo/hyper-carbia
Storage	Refrigerate at 2 to 8°C. Discard 12 hours after opening. Unopened, unused vials of beractant that have been warmed to room temperature can be returned to refrigerated storage within 8 hours for future use. Document on the packaging the date and time that the product was removed from the fridge. Do not warm to room temperature and return to the fridge more than once. Contact Pharmacy for further details.
Notes	For all indications, Survanta is the most cost-effective and hence preferred surfactant preparation, except in extremely preterm infants (≤25 weeks) where Curosurf is to be used or as per the Neonatal Consultant.
References	Truven Health Analytics. Beractant. In: NeoFax [Internet]. Greenwood Village (CO): Truven Health Analytics; 2017 [cited 2019 Aug 04]. Available from: https://neofax.micromedexsolutions.com/ Neomed Formularies. Beractant. Neomed Medication Guidelines [Internet] 2018 [updated Oct 2015; cited Dec 2018]

Document owner:	Head of Department - Neonatology		
Author / Reviewer:	KEMH & PCH Pharmacy / Neonatology Directorate		
Version Info:	Version 3.0 – full review (August 2019) Version 3.1 – amendment: removed reference to 5fg end hole catheter in administration section (November 2023)		
Date first issued:	October 2013	Version:	3.1
Last reviewed:	August 2019	Next review date:	August 2024
Endorsed by:	Neonatal Directorate Management Group	Date:	07/12/2023
Standards Applicable:	NSQHS Standards: 1  Governance 3  Infection Control 4  Medication Safety;		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from the WNHS website.			